Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis
Maturitas · 2025
DOI: 10.1016/j.maturitas.2025.108220 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Maturitas, 2025. Verfasst von Helen Michaela de Oliveira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Mato Grosso, Department of Medicine, Sinop, Mato Grosso, Brazil. Electronic address: helen.oliveira@sou.ufmt.br. Hauptthemen laut MEDLINE: Hot Flashes, Postmenopause, Pyrrolidines, Bridged-Ring Compounds. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE(S): Menopause, marked by a decline in estrogen, leads to disruptive vasomotor symptoms like hot flashes and night sweats, significantly affecting quality of life. This meta-analysis evaluated the efficacy and safety of fezolinetant and elinzanetant, two neurokinin 3 receptor antagonists, in managing vasomotor symptoms in postmenopausal women. METHODS: Data sources were identified by searches in PubMed, Embase, and the Cochrane Central Register of Controlled Trials up to September 2024. The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the risk of bias assessed using the version 2 of the Cochrane Risk of Bias Tool for Randomized Trials and evidence quality was evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach. Data were pooled using a random-effects model, and statistical analysis was performed using R version 4.4.1. RESULTS: Ten studies involving 4663 patients were included in the analysis. Elinzanetant >100 mg and fezolinetant ≤45 mg were the most effective doses for reducing vasomotor symptom frequency and severity. Fezolinetant (MD = -1.38) and elinzanetant (MD = -2.04) achieved ≥50 % reductions in vasomotor symptom frequency, with a greater effect in the elinzanetant group. Additionally, elinzanetant improved menopause-specific quality of life. However, higher doses of both drugs were associated with increased adverse effects, with elinzanetant demonstrating a more favorable side-effect profile than fezolinetant. CONCLUSIONS: Fezolinetant and elinzanetant are effective options for managing vasomotor symptoms. However, further research is needed to compare these treatments directly and evaluate their long-term safety profiles across different patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal University of Mato Grosso, Department of Medicine, Sinop, Mato Grosso, Brazil. Electronic address: helen.oliveira@sou.ufmt.br.
- Federal University of Triângulo Mineiro, Department of Medicine, Uberaba, Minas Gerais, Brazil.
- Federal University of Minas Gerais, Department of Medicine, Belo Horizonte, Minas Gerais, Brazil.
- State University of Rio de Janeiro, Department of Medicine, Rio de Janeiro, Rio de Janeiro, Brazil.
- Federal University of Pará, Department of Medicine, Belém, Pará, Brazil; University of Gurupi, Gynecology and Obstetrics, Gurupi, Tocantins, Brazil.
Zitieren
APA
de Oliveira, H. M., Diaz, C. A. V., Barbosa, L. M., Flávio-Reis, V. H. P., Zamora, F. V., & Gonçalves Barbosa Júnior, O. (2025). Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis. Maturitas. https://doi.org/10.1016/j.maturitas.2025.108220
Vancouver
de Oliveira HM, Diaz CAV, Barbosa LM, Flávio-Reis VHP, Zamora FV, Gonçalves Barbosa Júnior O. Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2025. doi:10.1016/j.maturitas.2025.108220
BibTeX
@article{deOliveira2025,
author = {de Oliveira, Helen Michaela and Diaz, Camilo André Viana and Barbosa, Lucas Mendes and Flávio-Reis, Victor Hugo Palhares and Zamora, Fernanda Valeriano and Gonçalves Barbosa Júnior, Osvaldo},
title = {Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis},
journal = {Maturitas},
year = {2025},
doi = {10.1016/j.maturitas.2025.108220}
}
EUVIMED